Certain Plant-Based Foods May Cut Crohn's Disease Risk
A high combined intake of fruits, vegetables, legumes, and potatoes was associated with a reduced risk for Crohn's disease — driven largely by specific foods such as apples or pears, bananas, mushrooms, and onions or garlic. Alternatively, a high intake of potatoes was associated with an increased risk for ulcerative colitis.
METHODOLOGY:
The International Organization for the Study of Inflammatory Bowel Disease recommends eating more fruits and vegetables for their fiber benefits, but current guidelines do not distinguish between subcategories despite their differing compositions and potential effects on inflammatory bowel disease (IBD) risk.
Researchers analyzed data of 341,519 participants without IBD (mean age, 52.1 years; 70% women) from a popular European cohort to evaluate how consumption of individual fruits, vegetables, legumes, and potatoes influenced the risk for Crohn's disease and ulcerative colitis.
At baseline, validated food frequency questionnaires were used to assess dietary intake of fruits, vegetables, legumes, and potatoes (including other tubers).
Participants in the lowest vs highest quartiles had median daily intakes of 291.6 vs 840.9 g/d of combined fruits, vegetables, legumes, and potatoes; 17.0 vs 100.3 g/d of apples/pears; 6.6 vs 14.0 g/d of bananas; 2.1 vs 6.2 g/d of mushrooms; 4.1 vs 11.9 g/d of onions or garlic; and 64.7 vs 82.1 g/d of potatoes.
TAKEAWAY:
The median follow-up period was 13.4 years, during which 149 participants developed Crohn's disease and 379 developed ulcerative colitis.
A higher combined intake of fruits, vegetables, legumes, and potatoes was associated with a lower risk of developing Crohn's disease (highest vs lowest quartile; adjusted hazard ratio [aHR], 0.44; 95% CI, 0.26-0.76) but not ulcerative colitis (aHR, 1.07; 95% CI, 0.76-1.50).
A subsequent post hoc analysis showed that the pooled intake of apples or pears, bananas, mushrooms, and onions or garlic was linked to a comparable risk reduction for Crohn's disease as total fruit, vegetable, legume, and potato intake (highest vs lowest quartile; pooled aHR, 0.58; 95% CI, 0.33-1.02).
However, a higher intake of potatoes was associated with a higher risk of developing ulcerative colitis (highest vs lowest quartile; aHR, 1.51; 95% CI, 1.05-2.17).
IN PRACTICE:
'In conclusion, we found that high combined intake of fruits, vegetables, legumes, and potatoes is associated with a lower risk of developing CD but not UC. This was particularly apparent for apple/pear, banana, mushrooms, and onion/garlic intakes. A higher risk of UC was observed for a higher intake of potatoes,' the authors of the study wrote.
SOURCE:
This study was led by Antoine Meyer, MD, PhD, Université Paris-Saclay, Villejuif, France. It was published online in the American Journal of Gastroenterology.
LIMITATIONS:
This study relied on food frequency questionnaires measured only at baseline, which may not have fully captured dietary changes over time. The mostly older, female population may not have represented the broader European or younger populations. As with all observational studies, residual confounding from unmeasured factors could not be ruled out.
DISCLOSURES:
The cohort was supported by the International Agency for Research on Cancer, the Department of Epidemiology and Biostatistics, School of Public Health, and other sources. Some authors declared receiving speaker fees, grants, consulting fees, and travel support from various pharmaceutical companies.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
If Another Home For Humanity Is Out There, This Spaceship Could Get Us There
Here's what you'll learn when you read this story: Project Hyperion competition winners dreamed up Chrysalis, a starship and space habitat that could make it to the planet Proxima b in just 400 years (which is ridiculously fast). The spacecraft is designed to run on a fusion engine, create artificial gravity, and carry about a thousand people while flying at around a tenth of the speed of light. Though Chrysalis remains a concept (for now), it could end up launching something unprecedented in the future. Headed towards the Proxima Centauri system, the starship Chrysalis traverses a seemingly endless expanse of space as it soars toward its final destination—the potentially habitable planet Proxima b. There, over a thousand passengers who have been living in the airborne habitat (the descendants of a crew that launched from Earth four centuries ago) will build a new frontier for humanity. Chrysalis sounds as if it flew straight out of a scene in Isaac Asimov's Foundation. But despite its sci-fi features, this is an actual spacecraft concept that recently won the Project Hyperion design competition hosted by the Initiative for Interstellar Studies (i4is). The craft is the brainchild of an interdisciplinary team of Italian researchers—Giacomo Infelise, Veronica Magli, Guido Sbrogio, Nevenka Martinello, and Federica Chiara Serpe—who were challenged to come up with a floating habitat that would eventually touch down on the closest exoplanet to Earth, Proxima b. 'The presentation is rich and visually engaging, drawing comparisons to iconic works like Rama, and showcasing a clear passion for both design and storytelling,' the competition jury said of Chrysalis in a recent press release. 'Its overall spacecraft design seems to take inspiration from the gigantic world ship concepts of the 1980s.' Each team that embarked on this conceptual journey needed at least one architectural designer, one engineer, and one social scientist. Their mission was to figure out how to accommodate a thousand (give or take 500) people over the centuries it would take for the spacecraft to reach its destination. Like the fictional starships it was inspired by, Chrysalis would to produce artificial gravity through a rotation system, in order to try and counteract the detrimental effects of microgravity on the human body. Designing support systems for food, water, waste, and an atmosphere—as well as coming up with ways to provide livable conditions and meet basic needs—were also mandatory parts of the contest. Additionally, there would need to be methods of transferring knowledge from generation to generations in order to both keep culture alive and retain (and advance) technology. The spacecraft would also have to trek through space at a maximum velocity of a tenth of the speed of light, and make it to Proxima b in as close to 250 years as possible. The fastest spacecraft to date is NASA's Parker Solar Probe, which recently zoomed past the Sun at a blazing 692,000 kmph (430,000 mph). But even Parker would still be short of one trillion miles (1.6 trillion km) after 224 years of travel, and still have over 24 trillion miles to go. If Chrysalis ever becomes a reality, it should make it to Proxima b in 400 years, after a year-long acceleration period. It would take another year to decelerate once it reached the planet. Proxima b is 4.24 light-years away, and one light-year equates to about 9.5 trillion km (6 trillion miles). So, the journey from here to Proxima b would cover 39 trillion km (25 trillion miles) through the void. Doing that in 400 years is certainly nothing to sneeze at. Much like the chrysalis of a moth or butterfly blown to epic proportions, Chrysalis was imagined as a 58,000-meter-long (63,430 yards), 2.4 billion-metric-ton (2.65 US tons) cylindrical structure. Its narrower front end would mitigate the risk of impacts from micrometeoroids, space junk, and anything else that could cause a damaging collision. The minimized front end is also meant to reduce stress on the spacecraft as it accelerates and decelerates. Powered by the nuclear fusion of helium and deuterium isotopes, its propulsion system would be a Direct Fusion Drive (DFD)—an engine that is still very much in the conceptual phase. It is supposed to give the spacecraft a simultaneous burst of electrical power and thrust. There is a reason that some floating off-earth habitats in science fiction are shown rotating in space. The front end of Chrysalis—which is imagined to function as the habitat—would have multiple levels in flexible modular shells that fit into each other and constantly rotate on one axis to maintain artificial gravity. From outer to inner, levels would be specialized for food production, ecosystems, communal spaces, housing, gardens, facilities, a warehouse, and the axial core. The Cosmo Dome at the front end is intended to be a bubble of microgravity that provides an incredible view to passengers as they experience weightlessness for a while. So, where do we go from here? Humans have yet to reach Mars (much less Proxima b), and whether such a massive concept can ever translate to reality remains to be seen. However, landing on the Moon was seen as an impossibility only a hundred years ago—the limits of humanity are possibly boundless. You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?
Yahoo
4 hours ago
- Yahoo
Forget the treadmill! I tried Nordic walking every day for a week — and it challenged me in ways I didn't expect
When you buy through links on our articles, Future and its syndication partners may earn a commission. From the viral trends of color walking and silent walking to the popular 5-2-4 Fartlek walking method, we've tested just about every walking workout going here at Tom's Guide. But Nordic walking — a technique that uses poles to turn a simple walk into a full-body workout — might just be one of the most intriguing yet. Often described as cross-country skiing without the snow, Nordic walking has been popular in parts of Europe for decades, especially in Scandinavia, where it's credited with boosting cardio fitness, improving posture, and reducing joint strain. As someone who loves low-impact exercise but still wants to feel results, I decided to pick up a pair of poles and give Nordic walking a go myself. After a week of daily Nordic walking, I noticed three key benefits that set it apart from a regular walk. It was more physically demanding than I expected — but in the best way. Here's what stood out. What is Nordic walking? Unlike the Japanese walking method, there's no interval training involved in Nordic walking. Originally developed in Finland as a way for cross-country skiers to stay fit in the off-season, Nordic walking involves walking with a pair of poles that help engage your upper body as you move. Rather than simply hiking with trekking poles, Nordic walking uses a specific motion: you plant the poles diagonally behind you and use them to help propel yourself forward with each step. It turns a regular walk into a full-body workout, activating the arms, shoulders, back and core, alongside your legs. In fact, research from the Cooper Institute suggests Nordic walking can burn between 20-46% more calories than normal walking at the same pace. It's also low-impact and joint-friendly, which makes it popular among people recovering from injury and older adults. That said, I don't fall into either of these categories, and I was still eager to give Nordic walking a go. I'm a pretty keen walker, and nothing quite helps me press the reset button — mentally as much as physically — like getting outside and moving my body. If Nordic walking is a way for me to scale up my daily walks so I can experience more of a cardio hit (and build strength to boot), then I'm all for it. After getting my hands on some poles (the OEX Ultralite Carbon Z Walking Poles from Go Outdoors, to be exact), I was only too eager to start the challenge. I live on the outskirts of a city, so while I'm close to public transport and pavement, I'm also lucky to have easy access to rural trails. But, once you get over the somewhat strange sensation of walking with poles, Nordic walking can be done pretty much anywhere — in parks, along sidewalks, or even in urban green spaces. Here are the three key benefits that stood out to me when trying Nordic walking. 1. My upper body *actually* got a workout I'll be honest — I didn't expect to feel this much in my arms. Upper body strength training is a key focus for me at the gym, so I (naively) assumed that I wouldn't find Nordic walking to be too challenging. I was wrong. From day one, I could feel my triceps and shoulders working as I pushed back with the poles. Nordic walking isn't just about holding the poles — it's about using them to propel yourself forward, which means your arms, back, chest, and even your core get involved. It felt a bit awkward at first, but once I found the rhythm, I could feel the difference. On a couple of mornings, I noticed some muscle fatigue in my upper body after finishing my walk — the kind of gentle soreness that tells you you've worked, but without the strain. It was a nice reminder that walking doesn't always have to be lower-body dominant, and Nordic walking offers a way to engage your whole body without stepping into a gym. 2. It improved my posture and walking form Once I got the hang of coordinating the poles with my stride, I started to notice how much better I was walking — not just during the workout, but throughout the day. Nordic walking forces you to stand tall, engage your core, and use a longer, more deliberate stride. I found myself naturally correcting my slouch and lifting through my chest to get the full benefit of the movement. As someone who swears by anti-desk exercises to keep my posture in check, I was pleasantly surprised. And because the poles help distribute your weight and provide support, I was also landing more evenly through my feet, rather than collapsing into my hips (something I tend to do when I'm tired). It was like getting a gentle reminder with every step to move with intention. 3. It was more mindful than I expected I went into this challenge thinking Nordic walking would be purely physical — a brisker version of my usual walk with the added bonus of some arm work. But what surprised me most was how mentally engaging it was. Because you're coordinating your arm swings with each step, there's a rhythm to it that demands focus, especially at the start. Without realizing it, I was paying more attention to my body — how I was moving, how upright I felt, where I was planting my feet. I wasn't scrolling on my phone or half-listening to a podcast. Being this present meant that by the end of each walk, I felt significantly calmer (which is no easy feat for someone with diagnosed ADHD). I'm yet to try walking yoga, so I'm not able to draw a direct comparison — but I can say that Nordic walking is a surprisingly effective way to feel more grounded. I tried Nordic walking every day for a week — my verdict Nordic walking was a lot more dynamic than I'd expected. It challenged my body in new ways, especially my upper body, and made me think more intentionally about how I move. I probably won't swap all my walks for pole-assisted ones, but I can definitely see the appeal — especially for people looking for low-impact, full-body cardio that's also friendly on the joints. If you've got access to walking poles (or want to invest in a pair), and you're looking for a way to shake up your current walking routine, what've you got to lose? Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button. More from Tom's Guide I followed the Japanese walking method for 30 days — here's what happened to my back pain and energy levels Forget running — 3 walking workouts that build lower body strength and burn calories Forget 10,000 steps — I tried 'rucking' instead of regular walking for one week, and it's a game changer
Yahoo
5 hours ago
- Yahoo
Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?
Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing serious headwinds. After enjoying a strong run fueled by demand for its obesity treatments, the obesity drug pioneer is now under pressure from rising competition, particularly from Eli Lilly's (LLY) weight-loss drugs, as well as trial setbacks for its next-generation therapies. In fact, things took a sharp turn on July 29, when the company cut its full-year sales growth guidance for the second time in just three months and named a new CEO. The market response was swift and brutal, with NVO shares plunging over 21% in a single day. Now, with second-quarter earnings just around the corner on Aug. 6, does Novo Nordisk's recent plunge present a golden buying opportunity, or is it a clear signal to keep your distance? More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! About Novo Nordisk Stock Best known for its blockbuster weight-loss drugs Ozempic and Wegovy, Novo Nordisk is a global healthcare leader with a long-standing focus on chronic disease. Founded in 1923 and headquartered in Denmark, the company has built a strong foundation in diabetes care while expanding its reach into obesity and other severe health conditions. The company commands a market capitalization of about $217.9 billion. While Novo Nordisk has been a trailblazer in the obesity drug market, its stock has hit a rough patch. Softer demand for its blockbuster drugs, combined with intensifying competition in the weight-loss space, has taken a toll on investor sentiment. The stock has tumbled a staggering 66% from its 52-week high of $139.74 reached in August 2024, and it's currently down 44.7% year-to-date (YTD). In stark contrast, the broader S&P 500 Index ($SPX) has managed to notch a gain of approximately 7.1% over the same period, while its rival Eli Lilly has seen only a marginal drop so far this year, highlighting just how far Novo has fallen out of favor with the market. Given its underwhelming price action, Novo Nordisk stock is starting to look like a value play. Currently trading at just 12.5 times forward earnings, it's priced well below the sector median of 16.87x, and dramatically lower than its own five-year average of 30.92x. Novo Nordisk's Q1 Earnings Snapshot In early May, Novo Nordisk posted a solid first-quarter earnings report for fiscal 2025, but the shine was dulled by a cautious outlook. Total revenue climbed 19% year-over-year (YOY) to 78.1 billion Danish kroner, powered by a massive 85% surge in Wegovy sales, which hit 17.4 billion Danish kroner. Ozempic also continued to perform, with sales rising 18% to 32.7 billion Danish kroner. Profits also impressed, with net profit climbing 14% to 29 billion Danish kroner, while operating profit increased 22% to 38.8 billion Danish kroner. But despite these promising numbers, Novo trimmed its full-year sales growth and operating profit growth guidance, citing 'lower-than-planned penetration of branded GLP-1 treatments in the US.' The company pointed to the growing presence of U.S. compounding pharmacies, which have been legally producing copycat versions of Wegovy and Ozempic under an FDA-approved exemption for addressing drug shortages. That growing parallel market has begun to chip away at Novo's momentum. On a more promising note, the company completed its REDEFINE 2 trial during the quarter, with its next-generation drug CagriSema delivering an impressive 15.7% weight loss in patients with obesity or overweight conditions and type 2 diabetes. Novo plans to file for its first regulatory approval in early 2026, potentially marking the next significant chapter in its obesity pipeline. Novo Nordisk Slashes Guidance Again and Names New CEO On July 29, Novo Nordisk held a conference call that left investors rattled, as it unveiled major leadership changes and another sharp downgrade to its 2025 financial outlook. The company slashed its full-year sales growth guidance to 8%-14%, down from the previously expected 13%-21%. Operating profit growth was also revised lower, now projected at 10%-16% compared to May's forecast of 16%-24%. The revised outlook sent a strong signal that Novo is bracing for a more challenging year ahead. A big part of the pressure comes from its obesity blockbuster, Wegovy. In its update, Novo pointed to several headwinds weighing on U.S. sales, including the continued rise of compounded GLP-1 knockoffs, slower-than-expected market expansion, and increasing competition. These challenges have clouded the outlook for one of Novo's key growth drivers, sparking concerns about whether the company can maintain its dominance in the rapidly growing weight-loss market. Adding to the uncertainty, Novo also announced a leadership shake-up. Maziar Mike Doustdar, the current EVP of international operations, will take over as CEO on Aug. 7, succeeding Lars Fruergaard Jørgensen, whose surprise resignation was announced in May. The transition comes at a pivotal moment, with the company under pressure to protect market share and reignite growth amid shifting dynamics in the obesity drug landscape. What Do Analysts Think About Novo Nordisk Stock? Despite all the swirling uncertainty, there's still a hint of optimism in the air. With Novo Nordisk set to unveil its Q2 earnings on Aug. 6 and a new CEO stepping in shortly after, Wall Street hasn't lost faith, with analysts leaning cautiously bullish, giving the stock a consensus rating of 'Moderate Buy' overall. Of the 19 analysts offering recommendations, seven advise a 'Strong Buy,' nine suggest a 'Hold,' one advocates a 'Moderate Sell,' and the remaining two maintain a 'Strong Sell.' NVO's average analyst price target of $71.75 suggests 47% potential upside from current levels. However, the Street-high target of $112 implies that shares can rally as much as 129.5% from current price levels. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
